Climb Bio (CLYM) Stock Forecast & Price Target

Q: What analysts cover Climb Bio?

Climb Bio has been rated by research analysts at B Riley , B. Riley Financial , BTIG Research , HC Wainwright , Oppenheimer , Piper Sandler , Robert W. Baird , Royal Bank Of Canada , Truist Financial , Wedbush , and Weiss Ratings in the past 90 days.

$15.81 +0.29 (+1.86%)

As of 01:04 PM Eastern

Compare

Climb Bio - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
1

Hold
0

Buy
15

Based on 16 Wall Street analysts who have issued ratings for Climb Bio in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 1 has given a sell rating, 14 have given a buy rating, and 1 has given a strong buy rating for CLYM.

Consensus Price Target

$26.92
70.30% Upside

According to the 16 analysts' twelve-month price targets for Climb Bio, the average price target is $26.92. The highest price target for CLYM is $40.00, while the lowest price target for CLYM is $18.00. The average price target represents a forecasted upside of 70.30% from the current price of $15.81.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for CLYM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Climb Bio and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLYM Analyst Ratings Over Time

Type	Current Forecast 9/8/25 to 9/8/26	1 Month Ago 8/9/25 to 8/9/26	3 Months Ago 6/10/25 to 6/10/26	1 Year Ago 9/8/24 to 9/8/25
Strong Buy	1 Strong Buy rating(s)	2 Strong Buy rating(s)	3 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	14 Buy rating(s)	12 Buy rating(s)	10 Buy rating(s)	2 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$26.92	$22.75	$21.64	$9.00
Forecasted Upside	70.30% Upside	62.50% Upside	100.34% Upside	264.37% Upside
Consensus Rating	Moderate Buy	Buy	Buy	Strong Buy

CLYM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CLYM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Climb Bio Stock vs. The Competition

Type	Climb Bio	Healthcare Companies	Broader Market
Consensus Rating Score	2.94	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	70.77% Upside	919.70% Upside	15.07% Upside
News Sentiment Rating	Positive News See Recent CLYM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/8/2026	HC Wainwright 4 of 5 stars	Raghuram Selvaraju 4 of 5 stars	Boost Target	Buy	$24.00 ➝ $30.00	+93.30%
9/4/2026	B Riley Not Rated		Reiterated Rating	Buy
9/4/2026	B. Riley Financial 4 of 5 stars	Mayank Mamtani 5 of 5 stars	Reiterated Rating	Buy	$26.00 ➝ $30.00	+89.93%
9/3/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yasmeen Rahimi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Overweight	$40.00	+182.49%
9/3/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Colleen Kusy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$21.00 ➝ $25.00	+72.41%
9/3/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Julian Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$20.00 ➝ $32.00	+120.69%
8/19/2026	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Chico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$20.00	+15.01%
8/7/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$17.00 ➝ $25.00	+74.42%
8/3/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$23.00	+93.28%
7/17/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
Get the Latest News and Ratings for CLYM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Climb Bio and its competitors with MarketBeat's FREE daily newsletter.
6/8/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yatin Suneja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$35.00	+231.75%
5/5/2026	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geulah Livshits Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$22.00	+127.04%
4/21/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leland Gershell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$10.00 ➝ $18.00	+89.31%
4/15/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Catanzaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$18.00	+103.39%
3/10/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Raymond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$25.00	+241.06%
10/16/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Phipps Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform
12/2/2024	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:04 PM ET.

CLYM Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Climb Bio is $26.92, with a high forecast of $40.00 and a low forecast of $18.00.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Climb Bio in the last twelve months. There is currently 1 sell rating, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CLYM shares.

According to analysts, Climb Bio's stock has a predicted upside of 70.30% based on their 12-month stock forecasts.

Climb Bio has been rated by research analysts at B Riley, B. Riley Financial, BTIG Research, HC Wainwright, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Truist Financial, Wedbush, and Weiss Ratings in the past 90 days.

Analysts like Climb Bio more than other "healthcare" companies. The consensus rating for Climb Bio is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how CLYM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Climb Bio Recommendations

MarketBeat monitors more than a dozen sources for Climb Bio analyst ratings, with the most recent rating issued on 9/8/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Climb Bio (CLYM) Stock Forecast & Price Target